DUBAI, UAE/PRNewswire/ -- Agiomix has received the ISO 15189:2012 Accreditation from the Emirates International Accreditation Centre for Next Generation Sequencing clinical assays.
This makes Agiomix the first and only clinical laboratory in the region to have both the CAP and ISO 15189 accreditation for its Next Generation Sequencing (NGS) clinical genetic testing.
Dr. Walaa Allam, Associate Director of Business development at Agiomix commented, "With this additional reputable international accreditation, Agiomix now has the unique capacity to offer its healthcare partners and patients, unparalleled clinical diagnostics services in the area of genetics, we are very pleased and honored by this accreditation and we look forward to more international recognition as our services and family grow."
Mr. Saman Setoudeh, Director of Quality Assurance at Agiomix Labs described the process the lab went through as being "rigorous and detailed", he also commended the review process and explained that "the ISO accreditation will add the Lab's strength and ability to lead the area in clinical genetics applications."
About Agiomix Labs
Agiomix is a leading Clinical Genetics and Specialty Diagnostics Laboratory, serving patients, healthcare providers and partner laboratories across the globe, with focus on the Middle East, Africa and Asia markets, Agiomix is both CAP and ISO 15189 accredited.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
